A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 54 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-10-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 10th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 17th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 233 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 112th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2016, is one of 121 in phase 3, and was the 213th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.
Inclusion criteria
Women of (WOCBP) must use an effective form of confirmed by the Investigator. WOCBP must also have negative serum pregnancy test result on Visit 1.
Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following agespecific requirements apply:
Additional inclusion criteria applicable for the Body Plethysmography substudy 1.Residual volume ≥125% of predicted at Visit 3.
Inclusion criteria at randomization visit
At least 1 of the following within 7 days prior to randomization:
Exclusion criteria
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
Current , or history of malignancy, except for:
Exclusion criteria at randomization Visit 4
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously
Drug: Benralizumab
Placebo administered subcutaneously
Other: Placebo
Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1
The average over the mean differences between benralizumab and placebo for change from baseline in pre-BD FEV1 is used to determine if the study is positive and to determine maintenance of effect. The first post baseline time point where the p-value for the mean difference between benralizumab and placebo is less than or equal to 0.05 is used to determine time to onset of effect.
Time frame: From first IP dose to Day 84
Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)
Body plethysmography was performed for sub-study patients. Lung volume subdivisions measures were performed by the investigator or qualified designee according to ATS/ERS guidelines.
Time frame: From first IP dose to Day 84
Percent Change From Baseline to End of Treatment in Eosinophils Counts
Percent change from baseline to Day 84
Time frame: From first IP dose to Day 84
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1
Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. \[Note: Day 28, 56, 84 are presented in the Primary measure.\]
Time frame: From first IP dose to Day 84
Change From Baseline to Post Baseline for Pre-BD FVC
Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, and Day 84.
Time frame: From first IP dose to Day 84
Percentage of Pre-BD FEV1 Responder
Pre-BD FEV1 responder is defined as change from baseline in FEV1 \>=100 ml
Time frame: From first IP dose to Day 84
Change From Baseline in ACQ-6
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
Time frame: From first IP dose to Day 84
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ)
The SGRQ is designed to measure health impairment in patients with asthma and COPD. It contains two parts: Part 1 (Questions 1 to 8) covers the patients' recollection of their symptoms over a preceding 4 weeks; Part 2, 42 items, relates to the daily activity and psychosocial impacts of the individual's respiratory condition. Total score is presented as a percentage of overall impairment, in which 100 represents the worst possible health status, while 0 indicates the best.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in FeNO
Airway inflammation was evaluated via fractional exhaled nitric oxide (FeNO) measurement.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
Time frame: From first IP dose to Day 84
Duration of IP Administration
Duration of IP administration is last IP dose date - first IP dose +1.
Time frame: From first IP to last IP
Serum Concentration of Benralizumab
PK sample was collected pre-dose at each visit
Time frame: From first dose to end of treatment period (Day 84)
PK Parameter of Benralizumab (Cmax)
PK parameters are derived in patients with at least three qualifiable serum PK concentrations post first dose (collected on Day 3, 7, and either 14, or 28)
Time frame: First IP dose cycle (ie, data collected on Days 3, 7, 14 and 28)
Anti-drug Antibody Responses
Anti-drug antibody responses at baseline and post baseline, including nAb responses
Time frame: From first IP dose to end of treatment period (Day 84)
Change From Baseline to End of Treatment in PGI-S
The patient global impression of severity (PGI-S) is a single item designed to capture the patient's perception of overall symptom severity at the time of the completion using a 6-point categorical response scale (no symptom \[0\] to very severe symptom \[5\])
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in CGI-C
Clinician global impression of change (CGI-C) is used for an overall evaluation of response to treatment. The investigator is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in PGI-C
Patient global impression of change (PGI-C) is used for an overall evaluation of response to treatment. The patient is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in Specific Airway Resistance (SGaw) for Sub-study Patients
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
Time frame: From first IP dose to Day 84
Change From Baseline to End of Treatment in Airway Resistance (Raw) for Sub-study Patients
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
Time frame: From first IP dose to Day 84
| Milestone | Benra 30 mg | Placebo |
|---|---|---|
| Started | 118 | 115 |
| Completed | 115 | 113 |
| Not completed | 3 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
The average over the mean differences between benralizumab and placebo for change from baseline in pre-BD FEV1 is used to determine if the study is positive and to determine maintenance of effect. The first post baseline time point where the p-value for the mean difference between benralizumab and placebo is less than or equal to 0.05 is used to determine time to onset of effect.
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Day 28 | 0.21 ± 0.335 | 0.132 ± 0.316 |
| Day 56 | 0.22 ± 0.367 | 0.203 ± 0.349 |
| Day 84 | 0.209 ± 0.344 | 0.149 ± 0.366 |
Body plethysmography was performed for sub-study patients. Lung volume subdivisions measures were performed by the investigator or qualified designee according to ATS/ERS guidelines.
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV) | -0.415 ± 0.609 | -0.208 ± 0.528 |
Percent change from baseline to Day 84
| Percent change | Benra 30 mg | Placebo |
|---|---|---|
| Percent Change From Baseline to End of Treatment in Eosinophils Counts | -88.55 (-100 to -12.5) | 11.55 (-91.4 to 833.3) |
Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. \[Note: Day 28, 56, 84 are presented in the Primary measure.\]
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Day 3 | 0.104 ± 0.223 | 0.081 ± 0.269 |
| Day 7 | 0.125 ± 0.229 | 0.081 ± 0.263 |
| Day 14 | 0.126 ± 0.3 | 0.1 ± 0.287 |
Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, and Day 84.
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Day 3 | 0.122 ± 0.247 | 0.11 ± 0.267 |
| Day 7 | 0.138 ± 0.277 | 0.099 ± 0.292 |
| Day 14 | 0.126 ± 0.331 | 0.111 ± 0.312 |
| Day 28 | 0.21 ± 0.347 | 0.134 ± 0.34 |
| Day 56 | 0.211 ± 0.404 | 0.187 ± 0.369 |
| Day 84 | 0.213 ± 0.376 | 0.131 ± 0.359 |
Pre-BD FEV1 responder is defined as change from baseline in FEV1 \>=100 ml
| Percentage of Participants | Benra 30 mg | Placebo |
|---|---|---|
| Day 3 | 48.2 | 37.4 |
| Day 7 | 48.3 | 42.0 |
| Day 14 | 50.0 | 38.9 |
| Day 28 | 57.6 | 46.9 |
| Day 56 | 62.1 | 55.8 |
| Day 84 | 57.9 | 51.8 |
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.
| Score on a scale | Benra 30 mg | Placebo |
|---|---|---|
| Day 14 | -0.989 ± 0.901 | -0.665 ± 0.837 |
| Day 28 | -1.126 ± 0.947 | -0.693 ± 0.869 |
| Day 56 | -1.164 ± 1.132 | -0.827 ± 1.023 |
| Day 84 | -1.355 ± 1.146 | -0.867 ± 1.114 |
The SGRQ is designed to measure health impairment in patients with asthma and COPD. It contains two parts: Part 1 (Questions 1 to 8) covers the patients' recollection of their symptoms over a preceding 4 weeks; Part 2, 42 items, relates to the daily activity and psychosocial impacts of the individual's respiratory condition. Total score is presented as a percentage of overall impairment, in which 100 represents the worst possible health status, while 0 indicates the best.
| Score on a scale | Benra 30 mg | Placebo |
|---|---|---|
| Day 28 | -16.956 ± 15.51 | -9.444 ± 14.136 |
| Day 56 | -19.941 ± 21.528 | -13.802 ± 16.705 |
| Day 84 | -23.343 ± 20.302 | -14.385 ± 18.836 |
Airway inflammation was evaluated via fractional exhaled nitric oxide (FeNO) measurement.
| ppb | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in FeNO | 5.92 ± 45.295 | 0.05 ± 27.634 |
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients | -0.276 ± 0.677 | -0.175 ± 0.418 |
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
| ratio | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients | -0.05 ± 0.056 | -0.026 ± 0.087 |
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients | 0.119 ± 0.447 | -0.268 ± 0.603 |
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients | -0.394 ± 0.783 | 0.093 ± 0.466 |
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
| Liter | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients | 0.139 ± 0.245 | 0.033 ± 0.676 |
Duration of IP administration is last IP dose date - first IP dose +1.
| Days | Benra 30 mg | Placebo |
|---|---|---|
| Duration of IP Administration | 55.9 ± 7.83 | 56.2 ± 7.61 |
PK sample was collected pre-dose at each visit
| ng/mL | Benra 30 mg |
|---|---|
| Baseline | 1.95 ± NA |
| Day 3 | 1266.78 ± 199.59 |
| Day 7 | 1449.47 ± 125.02 |
| Day 14 | 1317.92 ± 79.53 |
| Day 28 | 738.47 ± 80.77 |
| Day 56 | 1015.72 ± 59.74 |
| Day 84 | 1079.22 ± 73.24 |
PK parameters are derived in patients with at least three qualifiable serum PK concentrations post first dose (collected on Day 3, 7, and either 14, or 28)
| ng/mL | Benra 30 mg |
|---|---|
| PK Parameter of Benralizumab (Cmax) | 1729.6 ± 36.8 |
Anti-drug antibody responses at baseline and post baseline, including nAb responses
| Participants | Benra 30 mg | Placebo |
|---|---|---|
| ADA prevalence | 7 | 2 |
| nAb prevalence | 2 | 0 |
| Both baseline and post baseline positive | 1 | 2 |
| Only post baseline positive | 5 | 0 |
| Only baseline positive | 1 | 0 |
The patient global impression of severity (PGI-S) is a single item designed to capture the patient's perception of overall symptom severity at the time of the completion using a 6-point categorical response scale (no symptom \[0\] to very severe symptom \[5\])
| Score on a scale | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in PGI-S | -1.2 ± 1.31 | -0.8 ± 1.21 |
Clinician global impression of change (CGI-C) is used for an overall evaluation of response to treatment. The investigator is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.
| Participants | Benra 30 mg | Placebo |
|---|---|---|
| Very much improved | 18 | 10 |
| Much improved | 39 | 36 |
| Minimally improved | 39 | 28 |
| No change | 17 | 28 |
| Minimally worse | 0 | 7 |
| Much worse | 0 | 1 |
| Very much worse | 0 | 0 |
| Missing | 5 | 5 |
Patient global impression of change (PGI-C) is used for an overall evaluation of response to treatment. The patient is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.
| Participants | Benra 30 mg | Placebo |
|---|---|---|
| Very much improved | 32 | 17 |
| Much improved | 42 | 35 |
| Minimally improved | 23 | 29 |
| No change | 14 | 27 |
| Minimally worse | 1 | 4 |
| Much worse | 1 | 1 |
| Very much worse | 1 | 0 |
| Missing | 4 | 2 |
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
| 1/(kPa*sec) | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in Specific Airway Resistance (SGaw) for Sub-study Patients | -0.05 ± 0.146 | 0.052 ± 0.224 |
Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.
| kPa/L/sec | Benra 30 mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment in Airway Resistance (Raw) for Sub-study Patients | -0.233 ± 1.509 | -0.2 ± 0.532 |
Collected over From informed consent form was signed to end of study (ie, Day 112 follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30 mg | 0/118 (0%) | 1/118 (0.8%) | 28/118 (23.7%) |
| Placebo | 0/115 (0%) | 7/115 (6.1%) | 30/115 (26.1%) |
| Event | Benra 30 mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 0/118 | 2/115 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/118 | 2/115 |
| Coronary artery diseaseCardiac disorders | 0/118 | 1/115 |
| Lower respiratory tract infectionInfections and infestations | 0/118 | 1/115 |
| Generalised tonic-clonic seizureNervous system disorders | 0/118 | 1/115 |
| MigraineNervous system disorders | 0/118 | 1/115 |
| Drug hypersensitivityImmune system disorders | 1/118 | 0/115 |
| Event | Benra 30 mg | Placebo |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 11/118 | 18/115 |
| NasopharyngitisInfections and infestations | 8/118 | 6/115 |
| Upper respiratory tract infectionInfections and infestations | 6/118 | 6/115 |
| BronchitisInfections and infestations | 6/118 | 3/115 |
| Age, Continuous(years) | Benra 30 mg | Placebo | Total |
|---|---|---|---|
| Mean | 51.9 ± 13.62 | 50.9 ± 12.34 | 51.4 ± 12.99 |
| Sex: Female, Male(Participants) | Benra 30 mg | Placebo | Total |
|---|---|---|---|
| Female | 74 | 83 | 157 |
| Male | 44 | 32 | 76 |
| Race/Ethnicity, Customized(Participants) | Benra 30 mg | Placebo | Total |
|---|---|---|---|
| White | 69 | 67 | 136 |
| Black or African American | 3 | 4 | 7 |
| Asian | 39 | 40 | 79 |
| Other | 7 | 4 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Aug 2018, 20 months.
Results were first posted in Oct 2019, 1 year 2 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 20 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab